American Health Insurance Company Anthem, Inc. announced that the company has signed an agreement to takeover Aspire Health, the nation’s largest non-hospice, community-based palliative care provider.
With the unveiling of a new drug price plan by the Trump Administration, the Food and Drug Administration (FDA) will put into action a plan to infuse competition in drug markets.
On Monday Takeda Pharmaceutical confirmed to acquire Shire for £45.3 billion ($61.50 billion). The final deal will be 46 percent cash and 54 percent stock.
During the Fitbit Q1 earnings call, the company confirmed its focus on digital health regardless of the expected decline in sales numbers. Currently, Fitbit is focusing on its new alliance with Google, wherein the two companies will work together to speed up innovation in the digital health space to provide clear EHRs and precise patient data to help the clinicians.
In a bid to sweeten its deal for Fortis Healthcare, Manipal Health Enterprises has proposed merging of both enterprises that pegs the value of the beleaguered Fortis at Rs. 8,358 crores. The buyout efforts of Manipal have been backed by US private equity firm TPG.
In the first quarter of 2018, Swiss pharmaceuticals and diagnostics player Roche group’s sales rose by 6% to CHF 13.6 billion. Sales in the pharma division increased by 7% CHF 10.7 billion mainly by strong growth in Ocrevus and Perjeta.
T-Stealth™ Oncolytic Virus Platform Expected to Further Strengthen Immunotherapy Platform and Capabilities
Developing specialty vaccines for emerging and overlooked infectious diseases is a challenging and rewarding enterprise with specific opportunities and problems. Large companies have not historically prioritized this area and instead have focused on the development and commercialization of routine vaccines and vaccines for diseases with more significant global markets.
Akorn has filed a complaint in Delaware Chancery Court asking Fresenius to follow through on the pair's buyout agreement. A year after inking its $4.3 billion Akorn buyout agreement, Fresenius intends to scrap the deal. Akorn, though, isn’t having it, and analysts say a “legal battle royale” could be on the horizon.
Takeda has upped its offer to buy Shire $SHPG for a mix of stock and cash worth close to $65 billion, which is good enough for the Lexington, MA-based biotech to extend the deadline on their talks to May 8 after determining they were close to finalizing a pact.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.